AsemconnectVietnam - Before increasing capital, Vietnam Medical - Pharmaceutical Investment Joint Stock Company (code JVC - HOSE) established an additional company operating in the field of pharmaceutical business and other related industries.

Vietnam Medical - Pharmaceutical Investment approved the investment policy to establish a subsidiary called Vietnam Pharmaceutical Investment and Trading Joint Stock Company, with a charter capital of VND 250 billion, headquartered in Hanoi and operating mainly in the field of pharmaceutical business and other related industries.
Of which, Vietnam Medical - Pharmaceutical Investment will contribute VND245 billion, accounting for 98% of the charter capital of the new legal entity
Previously, Vietnam Medical - Pharmaceutical Investment approved the plan to offer 25 million shares privately at the offering price of VND10,000/share, raising VND250 billion, equivalent to 22.2% of the total number of outstanding shares and expected to be implemented from the fourth quarter of 2025.
Of the mobilized amount, the Company plans to use VND150 billion to contribute capital to Vietnam - Japan Medical Technology Investment Joint Stock Company and the remaining VND100 billion to supplement working capital.
In addition, Vietnam Medical - Pharmaceutical Investment also announced the list of investors expected to buy, which is VII Holding Joint Stock Company. In which, if the transaction is successful, VII Holding Joint Stock Company will increase its ownership from 0% to 18.2% of the charter capital of Vietnam Medical - Pharmaceutical Investment.
According to research, VII Holding Joint Stock Company was only established on May 29, 2024; address at DT 04-05-06, Ho Xuan Huong Street, Bach Viet Lake Garden New Urban Area, Bac Giang Ward, Bac Ninh Province; main activities in the field of investment consulting; and the legal representative is Mr. Vu Dinh Do.
It is worth noting that Ms. Nguyen Thi Hanh is a member of the Board of Directors at Vietnam Medical - Pharmaceutical Investment and Ms. Hanh also has a husband named Vu Dinh Do.
In fact, the plan to offer individual shares was approved at the 2024 General Meeting of Shareholders but has not been implemented, the Company continued to approve it at the 2025 General Meeting. However, at the 2025 General Meeting of Shareholders, shareholders also questioned the feasibility of the plan to offer individual shares.
The Board of Directors of Vietnam Medical - Pharmaceutical Investment said that, stemming from the Company's need for additional capital to invest in expanding the business activities of the Company and its Subsidiaries, the Company has considered and decided to submit a plan to issue individual shares in 2024. However, due to the unfavorable market situation, the offering of individual shares to investors in 2024 has not been implemented.
The Company has contacted and worked with a number of potential investors, the parties need more time to thoroughly research and evaluate the suitability. If an agreement is reached combined with favorable market conditions in 2025, the Board of Directors of Vietnam Medical - Pharmaceutical Investment assesses that the issuance of individual shares will be successfully implemented.
N.Nga
Source: VITIC/Tinnhanhchungkhoan